Galderma Shares Drop After FDA Again Refuses U.S. Approval for RelabotulinumtoxinA
Shares of Swiss dermatology firm Galderma fell about 6% after the U.S. Food and Drug Administration issued a Complete Response Letter for RelabotulinumtoxinA, marking a second U.S. regulatory setback tied to manufacturing-related observations. The company said it will take corrective and preventive actions and engage with the regulator while stress…